Leukemia· 2022Q1· Review
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- 3,967citations
- Q1SCImago
- 2022year
Short summary
The 5th edition of the WHO Classification of Haematolymphoid Tumours refines diagnostic criteria for myeloid and histiocytic/dendritic neoplasms, emphasizing therapeutically actionable biomarkers and molecular biology.
AI-generated from the title and abstract; the full text is not read.
Key points
- Updated classification for myeloid and histiocytic/dendritic neoplasms.
- Refined diagnostic criteria based on clinicopathologic parameters.
- Increased emphasis on actionable biomarkers for therapy and prognosis.
- Integration of molecular biology findings into disease definitions.
- Designed for global applicability and future updates.
AI-generated from the title and abstract; the full text is not read.
Abstract
The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.
The authors' abstract, as published at the source. Leukemia, 2022 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine